Wikipedia -WSS

Wikipedia

author：focus 2025-10-01 01:00:37 - browse：19

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： What do new weight loss drugs mean for bariatric surgery?

focus

WSS

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Australia’s approach to dialysis celebrates life

Study finds new variant for Parkinson’s in African populations

Meadows told special counsel he could not recall Trump ever declassifying Mar

FDA greenlights medical device to combat bladder issues

Neuroscience startup Neumora files for IPO

entertainment

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

As pharma fights Medicare drug negotiation, hospitals, docs silent

Walensky prepares to leave CDC — and Congress — behind

Psilocybin's anti

Bright Health sells Medicare Advantage business to Molina

In science, is the line between industry and academia shifting?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Departing Stanford president retracts two papers

Medicare details structure of new drug price negotiation program

Kellogg’s is going to war over Mexico’s nutrition label rules

entertainment

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Study finds new variant for Parkinson’s in African populations

Intellia plays down concerns on accidental germline transmission

Diversity in medical illustrations gets boost from Chidiebere Ibe

How to make over

In science, is the line between industry and academia shifting?

focus

Wikipedia

focus

leisure time